[go: up one dir, main page]

CA2247814A1 - Composes pharmaceutiquement utiles - Google Patents

Composes pharmaceutiquement utiles Download PDF

Info

Publication number
CA2247814A1
CA2247814A1 CA002247814A CA2247814A CA2247814A1 CA 2247814 A1 CA2247814 A1 CA 2247814A1 CA 002247814 A CA002247814 A CA 002247814A CA 2247814 A CA2247814 A CA 2247814A CA 2247814 A1 CA2247814 A1 CA 2247814A1
Authority
CA
Canada
Prior art keywords
pyrazolo
hydroxy
bond
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002247814A
Other languages
English (en)
Inventor
Mark Furber
John Bantick
Simon Hirst
Roger Bonnert
Matthew Perry
David Donald
Eifion Phillips
Peter Cage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605803.7A external-priority patent/GB9605803D0/en
Priority claimed from GBGB9610474.0A external-priority patent/GB9610474D0/en
Priority claimed from GBGB9610894.9A external-priority patent/GB9610894D0/en
Priority claimed from GBGB9700862.7A external-priority patent/GB9700862D0/en
Application filed by Individual filed Critical Individual
Publication of CA2247814A1 publication Critical patent/CA2247814A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dérivés de 2-arylpyrazolisoquinoline et de cinnolinone, procédés de préparation de ces dérivés, leur utilisation comme médicament et formulations pharmaceutiques renfermant ces dérivés.
CA002247814A 1996-03-20 1997-03-20 Composes pharmaceutiquement utiles Abandoned CA2247814A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9605803.7 1996-03-20
GBGB9605803.7A GB9605803D0 (en) 1996-03-20 1996-03-20 Pharmaceutically-active compound
GB9610474.0 1996-05-18
GBGB9610474.0A GB9610474D0 (en) 1996-05-18 1996-05-18 Pharmaceutically active compounds
GB9610894.9 1996-05-24
GBGB9610894.9A GB9610894D0 (en) 1996-05-24 1996-05-24 Pharmaceutically useful compounds
GBGB9700862.7A GB9700862D0 (en) 1997-01-16 1997-01-16 Pharmaceutically useful compounds
GB9700862.7 1997-01-16

Publications (1)

Publication Number Publication Date
CA2247814A1 true CA2247814A1 (fr) 1997-09-25

Family

ID=27451427

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247814A Abandoned CA2247814A1 (fr) 1996-03-20 1997-03-20 Composes pharmaceutiquement utiles

Country Status (19)

Country Link
EP (1) EP0888347A1 (fr)
JP (1) JP2000506884A (fr)
KR (1) KR20000064716A (fr)
CN (1) CN1218472A (fr)
AR (1) AR006520A1 (fr)
AU (1) AU712141B2 (fr)
BR (1) BR9708103A (fr)
CA (1) CA2247814A1 (fr)
CZ (1) CZ297798A3 (fr)
EE (1) EE9800298A (fr)
ID (1) ID16283A (fr)
IL (1) IL126271A0 (fr)
IS (1) IS4848A (fr)
NO (1) NO984290L (fr)
NZ (1) NZ331614A (fr)
PL (1) PL328921A1 (fr)
SK (1) SK118798A3 (fr)
TR (1) TR199801861T2 (fr)
WO (1) WO1997034893A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
JP2003002863A (ja) * 2001-06-25 2003-01-08 Nippon Soda Co Ltd 安息香酸類の製造方法および新規化合物
US6642249B2 (en) 2001-07-04 2003-11-04 Active Biotech Ab Immunomodulating compounds
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
DE10229762A1 (de) * 2002-07-03 2004-01-22 Aventis Pharma Deutschland Gmbh Pyrazoloisoquinolinenderivaten zur Inhibierung von NFkappaB-induzierende Kinase
US7081456B2 (en) * 2002-11-22 2006-07-25 Active Biotech Ab Immunomodulatory compounds
WO2004055014A1 (fr) * 2002-12-16 2004-07-01 Active Biotech Ab Composes immunomodulateurs tetracycliques
BRPI0408365B8 (pt) 2003-03-14 2021-05-25 Avidex Ltd compostos heterocíclicos de imunomodulação
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
JP2007516258A (ja) 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DE602004017231D1 (de) * 2004-08-09 2008-11-27 Medigene Ltd Immunmodulierende oxopyrazolocinnoline als cd80-inhibitoren
GEP20115239B (en) 2006-10-31 2011-06-10 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptor antagonists
CN102372710A (zh) 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
BR112013020282A2 (pt) 2011-02-09 2017-07-18 Nissan Chemical Ind Ltd derivado pirazol e agente de controle
DK3846904T3 (da) * 2018-09-07 2023-08-21 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
HRP20250814T1 (hr) 2020-07-02 2025-09-12 Incyte Corporation Spojevi tricikličke uree kao jak2 v617f inhibitori
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (fr) 2020-12-21 2022-06-30 Incyte Corporation Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
CA3211748A1 (fr) 2021-02-25 2022-09-01 Incyte Corporation Lactames spirocycliques utilises comme inhibiteurs du v617f de jak2
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
CN119638634A (zh) * 2023-09-18 2025-03-18 上海赛默罗生物科技有限公司 噌啉-2-氧化物类化合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524146A (en) * 1982-12-08 1985-06-18 Ciba-Geigy Corporation Certain -2-heterocycle substituted pyrazoloquinolines
JPS61112075A (ja) * 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
SE8903564D0 (sv) * 1989-10-26 1989-10-26 Pharmacia Ab New use condensed quinoline compound
JPH05194515A (ja) * 1991-07-31 1993-08-03 Kyowa Hakko Kogyo Co Ltd 縮合ナフチリジン誘導体

Also Published As

Publication number Publication date
IS4848A (is) 1998-09-16
IL126271A0 (en) 1999-05-09
JP2000506884A (ja) 2000-06-06
EE9800298A (et) 1999-02-15
AU712141B2 (en) 1999-10-28
NO984290D0 (no) 1998-09-16
NZ331614A (en) 2000-07-28
EP0888347A1 (fr) 1999-01-07
TR199801861T2 (xx) 1998-12-21
NO984290L (no) 1998-10-27
ID16283A (id) 1997-09-18
AR006520A1 (es) 1999-09-08
WO1997034893A1 (fr) 1997-09-25
KR20000064716A (ko) 2000-11-06
SK118798A3 (en) 1999-03-12
AU2186797A (en) 1997-10-10
BR9708103A (pt) 1999-07-27
CZ297798A3 (cs) 1999-03-17
PL328921A1 (en) 1999-03-01
CN1218472A (zh) 1999-06-02

Similar Documents

Publication Publication Date Title
CA2247814A1 (fr) Composes pharmaceutiquement utiles
CA2166721C (fr) Tetrahydropyrazolopyridines bicycliques
JP2862375B2 (ja) Ｃｒｆアンタゴニストとしてのピラゾロピリミジン
US5134142A (en) Pyrazole derivatives, and pharmaceutical composition comprising the same
US4810719A (en) Anti-inflammator 1,n-diarylpyrazol-3-amines
AU2002352425A1 (en) 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
JP2003511452A (ja) ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
JPH0256484A (ja) 縮合ピリミジン誘導体およびその製造方法
JPH07509725A (ja) Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
WO1995028387A1 (fr) Compose benzamide et utilisation medicale dudit compose
JP2008525404A (ja) 治療剤
JP2002508780A (ja) 新規な化合物
KR20000069605A (ko) 피롤로[3,4-ｄ]피리미디논 유도체 및 약제로서의 이의 용도
WO2003033478A1 (fr) Composes pyrimidiques a anneaux fusionnes alcynyles servant d'inhibiteurs de la metalloprotease matricielle de type 13
AU639043B2 (en) Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0517470A (ja) ピラゾール誘導体
JP2002507988A (ja) 化合物
JP2007531723A (ja) 治療薬
RU2116308C1 (ru) Триазолпиримидиновые производные и фармацевтическая композиция
JPH0768228B2 (ja) アリールトリアジン構造を有する新規化合物、その製造方法並びにこれを含む医薬組成物
JPH0378854B2 (fr)
JPH0528701B2 (fr)
US7148222B2 (en) Substituted pyrido-pyridazine derivatives which enhance cognition via the GABA-A receptors
JP2001509509A (ja) 新規な化合物
KR900001885B1 (ko) 5-클로로-s-트리아졸로[4, 3-a]피리딘-7-카복실산 및 그의 제조방법

Legal Events

Date Code Title Description
FZDE Discontinued